Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Don't think for a second that the biotech stock can't move higher.

3 Reasons It's Not Too Late to Buy Moderna Stock

A key FDA panel is scheduled to vote Thursday on whether to recommend the approval of Moderna's Covid-19 vaccine for emergency use.

5 things to know before FDA panel votes on Moderna's Covid vaccine today

Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine

Moderna Vaccine: The Power of mRNA Technology

Home Depot

Texas Instruments

A certain 30 companies come to mind when blue-chip stocks are discussed, but don't overlook the opportunity to profit elsewhere too The post 3 Blue-Chip Stocks to Sell appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

3 Blue-Chip Stocks to Sell

A day ahead of an FDA panel meeting for Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, an analyst at Morgan Stanley stepped to the sidelines on the stock.  The Moderna Analyst: Matthew Harrison downgraded Moderna from Outperform to Equal-weight and raised the price target from $100 to $150.

Moderna Analyst: COVID-19 Vaccine Value Largely Reflected In Stock

An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.

Moderna (MRNA) Vaccine May Get Emergency Approval This Week

If the Food and Drug Administration authorizes Moderna Inc.'s COVID-19 vaccine candidate, it will be the second vaccine made available to Americans during the coronavirus pandemic --- and the first-ever authorized product for the 10-year-old biotech.

Moderna nears its first-ever FDA authorization, for its COVID-19 vaccine

Pfizer

Moderna and Pfizer have quickly developed highly effective vaccines that should help to end the Covid-19 pandemic. With Pfizer's vaccine already rolling out in the U.K, and the U.S. in limited quantities, and Moderna's likely to follow suit in the coming weeks, investors are likely trying to.

Pfizer And Moderna's Vaccines Could Be More Profitable Than You Think

Moderna Inc (NASDAQ:MRNA) made headlines recently, after the Food and Drug Administration (FDA) scientists gave the drugmaker's COVID-19 vaccine favorable reviews.

MRNA Poised to Fall Following Double Dose of Downgrades

BioNTech SE

The Moderna and Pfizer vaccines have one key similarity.

What Pfizer's Vaccine Authorization Means for Moderna

AstraZeneca

Sanofi

The challenges for two big drugmakers could translate to opportunities for their rivals in the COVID-19 vaccine race.

Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

Investors didn't necessarily like what Dr. Fauci had to say about coronavirus vaccines.

Why Moderna Got Slammed on Tuesday

  Moderna fell as much as 7.2% on Tuesday after the US Food and Drug Administration recommended monitoring recipients of its COVID-19 vaccine for possible cases of Bell's palsy.

Moderna slides 7% after FDA confirms vaccine's effectiveness but cautions on Bell's palsy in recipients

On a positive note, the data shows the shots were generally better tolerated by people over 64 who are also among the most vulnerable to the disease.

FDA says fatigue, headaches and muscle pain are the most common side effects of Moderna's Covid vaccine

Moderna Inc's (NASDAQ: MRNA) application requesting emergency use authorization for its coronavirus vaccine candidate will discussed by FDA's Vaccines and Related Biological Products Advisory Committee Thursday. The briefing document prepared by FDA staff to aid discussions at the Adcom meeting shows a favorable disposition toward the vaccine candidate

FDA Briefing Document On Moderna's Coronavirus Vaccine Positive On Efficacy, Safety

If approved, it will be the second Covid-19 vaccine authorized for emergency use in the U.S..

FDA Endorses Moderna Covid-19 Vaccine After Review Confirms Safety And Efficacy

Moderna Inc.'s (NASDQ: MRNA) COVID-19 vaccine could be shipped as early as Sunday, but to five times as many distribution points as Pfizer Inc.'s (NYSE: PFE) product is heading to in its initial wave, according to federal officials. But maintaining adequate safety stock is a key consideration in both cases.

More than 3,000 sites to receive Moderna COVID vaccine

Millions more Americans could get access to COVID-19 vaccines within days. The US Food and Drug Administration will authorize biotech company Moderna's COVID-19 vaccine on Friday, sources close to the agency told the The New York Times. The move would allow millions of Americans to get access to the vaccine by next week, per the Times.

The FDA will likely grant Moderna's COVID-19 vaccine emergency use authorization on Friday

Another COVID-19 vaccine is on the verge of authorization after an FDA analysis determined Moderna's vaccine as safe and “highly effective.

FDA says Moderna's COVID-19 vaccine, which began its trials in Seattle, is ‘highly effective'

The FDA said that there were four reported cases of Bell's palsy among Moderna's 30,000 trial participants, including three who got the vaccine.

FDA staff recommends watching for Bell's palsy in Moderna and Pfizer vaccine recipients

Moderna stock edged higher Tuesday after Food and Drug Administration documents seemingly endorsed the company's experimental coronavirus vaccine for emergency use authorization. The post Moderna Stock Rises As FDA Appears Ready To Authorize Covid Vaccine appeared first on Investor's Business Daily.

Moderna Stock Rises As FDA Appears Ready To Authorize Covid Vaccine

The data appear to show that Moderna's vaccine prevents most cases of asymptomatic infection after one dose, which would help reduce the spread of the virus significantly.

Moderna's Covid-19 Vaccine Is “Highly Effective,” FDA Says

The US is close to approving a second COVID-19 jab for use, as the country ramps up its vaccination programme.

Moderna vaccine nears approval in US as rollout of Pfizer jab continues

FedEx

Trane Technologies plc

Emergency approval of COVID-19 vaccines is a boon for stocks such as Trane Technologies (TT), United Parcel Service (UPS), FedEx (FDX), Pfizer (PFE) and Moderna (MRNA). Here's why -

5 Stocks to Win Big as Coronavirus Vaccine Rollout Begins

The Food and Drug Administration released documents detailing Moderna's coronavirus vaccine candidate's "favorable safety profile" on Tuesday ahead of a key committee meeting scheduled for Thursday.

News for Moderna Stock (MRNA)